ANT 1403

Drug Profile

ANT 1403

Alternative Names: ANT-1403

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Anterios
  • Class Biological factors; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hyperhidrosis

Most Recent Events

  • 31 Jul 2013 Anterios completes a phase II trial in Hyperhidrosis in USA (NCT01799824)
  • 21 Jun 2013 Anterios completes enrolment in its phase II trial for Hyperhidrosis in USA (NCT01799824)
  • 26 Feb 2013 Phase-II clinical trials in Hyperhidrosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top